PDU is currently being tested as an aid to diagnosing prostate cancer. Our attempt has been to verify its usefulness to improve effectiveness of eight core TR biopsy. Two groups of patients were examined for increased PSA with or without a palpable prostatic nodule. The first group was composed by 52 patients between 55 and 83 years of age (mean 69.57) with PSA values between 0.87 and 94.91 ng/ml (8.085 +/- 14.056) of which 29 (55.75%) showed a palpable nodule. All patients underwent prostatic eight core TR echobiopsy. The second group was composed by 56 patients between 49 and 84 years of age (mean 69,19) with PSA values between 1.14 and 59.7 ng/ml (8.74 +/- 12.977) of which 33 (58.97%) showed a palpable nodule. This group of patients underwent a PDU just before TR biopsy in order to assess prostatic blood supply and locate possible alterations. Prostatic volume in both groups was never higher than 50 cc. Of the first group 25 patients (48.08%) were prostate cancer positive. Of the second group 31 patients (55.36%) were positive to a biopsyfor prostate cancer. In addition 22 out of the 31 showed a palpable nodule and vascular irregularity. PDU is being tested in order to reduce the number of biopsies and tissue samplings. The above results (tests carried out by the same operator with two homogeneous groups of patients) show how PDU was useful in diagnosing a higher number of prostate cancers. We could therefore safely conclude that the use of PDU in association with TR biopsy greatly increases diagnostic sensitivity and specificity.

Download full-text PDF

Source

Publication Analysis

Top Keywords

prostate cancer
12
palpable nodule
12
group patients
12
patients
8
groups patients
8
nodule group
8
group composed
8
composed patients
8
patients years
8
years age
8

Similar Publications

Coding Variants of the Genitourinary Development Gene Carry High Risk for Prostate Cancer.

JCO Precis Oncol

January 2025

Medical Research Service, Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN.

Purpose: Considerable genetic heterogeneity is currently thought to underlie hereditary prostate cancer (HPC). Most families meeting criteria for HPC cannot be attributed to currently known pathogenic variants.

Methods: To discover pathogenic variants predisposing to prostate cancer, we conducted a familial case-control association study using both genome-wide single-allele and identity-by-descent analytic approaches.

View Article and Find Full Text PDF

Neuroendocrine neoplasms (NENs) encompass a diverse set of malignancies with limited precision therapy options. Recently, therapies targeting DLL3 have shown clinical efficacy in aggressive NENs, including small cell lung cancers and neuroendocrine prostate cancers. Given the continued development and expansion of DLL3-targeted therapies, we sought to characterize the expression of DLL3 and identify its clinical and molecular correlates across diverse neuroendocrine and non-neuroendocrine cancers.

View Article and Find Full Text PDF

Objective: A new library of Thiazolidine-2,4-dione-biphenyl Derivatives derivatives (10a-j) was designed and synthesized. All compounds were characterized by spectral data. Further, these were evaluated for their in vitro anticancer activity.

View Article and Find Full Text PDF

Objective: This study aimed to investigate the influence of p16 immunohistochemical expression on the biochemical recurrence rate of pT2-pT3 prostate cancer.

Materials And Methods: A total of 488 pT2-pT3 stage prostate adenocarcinomas undergoing radical prostatectomy were included in this study. Following a review of Gleason classification and retrieval of sociodemographic and clinicopathological data, as well as the date of last consultation and biochemical recurrence, immunohistochemistry for p16 was performed.

View Article and Find Full Text PDF

Among the known nuclear exportins, CRM1 is the most studied prototype. Dysregulation of CRM1 occurs in many cancers, hence, understanding the role of CRM1 in cancer can help in developing synergistic therapeutics. The study investigates how CRM1 affects prostate cancer growth and survival.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!